eric
12-11-2004, 07:21 PM
http://biz.yahoo.com/prnews/041211/sfsa001_1.html
Dendreon Corporation (Nasdaq: DNDN - News) today announced results from two Phase 1 studies demonstrating promising clinical activity of the company's investigational immunotherapy, APC8024, in HER2/neu positive advanced breast cancer. Michelle Melisko M.D., Clinical Instructor, Carol Franc Buck Breast Care Center, University of California Comprehensive Cancer Center, San Francisco, presented the findings today at the 27th Annual San Antonio Breast Cancer Symposium.
"APC8024 represents the expansion of our immunotherapy platform into other solid tumors," said Robert Hershberg, M.D., Ph.D., senior vice president and chief medical officer at Dendreon Corporation. "We believe APC8024 could provide physicians with a highly targeted and well-tolerated therapy for treating patients with breast cancer. Based on the encouraging data from these two Phase 1 studies, we are planning to initiate a Phase 2 trial with APC8024 in metastatic breast cancer in the coming year."
Dendreon Corporation (Nasdaq: DNDN - News) today announced results from two Phase 1 studies demonstrating promising clinical activity of the company's investigational immunotherapy, APC8024, in HER2/neu positive advanced breast cancer. Michelle Melisko M.D., Clinical Instructor, Carol Franc Buck Breast Care Center, University of California Comprehensive Cancer Center, San Francisco, presented the findings today at the 27th Annual San Antonio Breast Cancer Symposium.
"APC8024 represents the expansion of our immunotherapy platform into other solid tumors," said Robert Hershberg, M.D., Ph.D., senior vice president and chief medical officer at Dendreon Corporation. "We believe APC8024 could provide physicians with a highly targeted and well-tolerated therapy for treating patients with breast cancer. Based on the encouraging data from these two Phase 1 studies, we are planning to initiate a Phase 2 trial with APC8024 in metastatic breast cancer in the coming year."